Gerresheimer has entered into a partnership with the US digital health company RxCap and acquired a minority stake.
Gerresheimer
Under the terms of the agreement, Gerresheimer's subsidiary Centor will receive the exclusive distribution rights for pharmacies in the US for adherence solutions by RxCap, consisting of connected prescription vial closure devices and complementary cloud-based software.
Patient adherence to medication is crucial for therapy outcome and can prevent cost-intensive hospitalisations. Digital therapy support is becoming increasingly important in this area, not only through body-worn sensors and apps, but also through connected primary packaging and delivery systems and medication adherence monitoring.
Under the partnership agreement Centor will offer RxCap’s suite of connected prescription vial closure devices and complementary cloud-based software to pharmacies to help them monitor their patients’ prescription adherence.
This partnership will enable pharmacies to quickly launch adherence solutions that can support patient’s health journey more effectively, with minimal additional investments in their workflow, and create new revenue streams.